Business
Futura update on CBD100 1st Stage Development Work
Futura update on CBD100 1st Stage Development Work.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \n \n RNS Number : 9846U\n Futura Medical PLC\n 04 August 2020\n \n \n \n \n 4 August 2020\n \n \n \n \n \n \n Futura update on Cannabidiol Dermasys\n \n \n ®\n \n \n (CBD100) First Stage Development Work \n \n \n \n \n \n Futura Medical plc (AIM: FUM) (\"Futura\" or the \"Company\"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, announces completion of initial laboratory and optimisation work on a Dermasys® cannabidiol gel (CBD100) under the joint venture collaboration agreement with CBDerma Technology Limited that was announced in September 2019.\n \n As part of a robust formulation process using strict pharmaceutical development principles, Futura has carried out extensive Dermasys Cannabidiol formulation work and initial in vitro tests on human epidermis. The studies demonstrate highly efficient penetration of cannabidiol into and through the skin, superior to an established, marketed, comparator product. Additionally, cannabidiol is known to be unstable with many common excipients. The Dermasys Cannabidiol gel was specially formulated to minimise this issue and is showing encouraging early stability work, which is expected to ensure potency is retained during shelf-life.\n \n \n James Barder, Chief Executive of Futura Medical commented: \"Our R&D team's development work on CBD100 is further evidence of the broad utility and power of the Dermasys system for effective and controlled transdermal delivery of a wide range of active pharmaceutical ingredients (APIs). We are aiming for CBD100 to be highly differentiated from existing, largely un-regulated, low-tech products in the fast growing cannabidiol market on the basis of quality, stability and efficient delivery to the skin for a number of applications and indications expected to range from cosmeceutical through to pharmaceutical dermal and pain relief treatments. We have now started to explore commercialisation options for CBD100 with CBDerma as stability work continues in parallel.\"\n \n -ENDS-\n \n For further information please contact:\n \n \n Futura Medical plc \n \n \n James Barder, Chief Executive \n \n \n Angela Hildreth, Finance Director and COO \n \n \n Email: \n \n Inv...